UK Startup BioOrbit Sends DrugCrystallization Technology to Space for Cancer Treatment Development CBS Cancels The Late Show With Stephen Colbert Shifts LateNight Strategy With Comics Unleashed Michael Saylor Tokenization May Create a Free Market in Credit and Yield Challenging Traditional Banking Yaashvi Jewellers IPO Day 1 Sees Tepid Demand with 2 Subscription CNBCs Charitable Trust Trims Stock That Surged 46 in a Week 80 Since April Brainbees Solutions Q4 Results Firstcry Parent Narrows Net Loss Revenue Up 12 FactSet Q1 2026 Earnings EPS Beat Drives Positive Market Response Stardust Power Inc SDST Q1 2026 Earnings EPS Misses Estimates as PreRevenue Company Focuses on Development Norfolk Southern Q1 2026 Earnings Rail Operator Beats EPS Estimates Amid Operational Resilience LAC Q1 2026 Earnings Lithium Developer Beats on EPS Stock Gains on Progress INVX Q1 2026 Earnings EPS Surges 1015 Above Estimates Revenue Not Disclosed Stock Declines 25 SLP Q1 2026 Earnings EPS Beats Estimates by 1028 Shares Rise 588 Lennox International Holds Steady Near Midpoint of Key Range as Volume Remains Moderate Coincheck Group CNCK Slides 276 as CryptoRelated Volatility Persists RLI Corp RLI Edges Lower Testing Support Territory Near 4993 Calamos Global Dynamic Income Fund CHW Rallies 172 Approaching Key Resistance Columbus Circle Capital Corp II CMII Holds Steady Near 991 Amid Flat Trading UCB Q1 2026 Earnings EPS Slightly Misses Estimates Amid Positive Market Reaction Virgin Galactic Q1 2026 Earnings Loss Narrows as Company Reports BetterThanExpected EPS CVR Energy Q1 2026 Earnings Substantial EPS Miss Amid Challenging Refining Environment Nasdaq Inc NDAQ Q1 2026 Earnings EPS Surpasses Estimates as Stock Ticks Higher BWMX Q1 2026 Earnings EPS Misses Expectations Despite Slight Stock Uptick GTES Q1 2026 Earnings EPS Beats Estimates Revenue Details Limited EU Green Economy Output Doubles as Solar Energy Surges to Record Levels SOC Q1 2026 Earnings EPS Falls Sharply Below Estimates Stock Rallies ADMA Biologics Slides 109 Key Support Levels in Focus Amid Biotech Headwinds